14:00 , Apr 11, 2019 |  BC Extra  |  Financial News

TPG, Vida back Asklepios in $235M round

TPG Capital and Vida Ventures have again teamed up to invest in a biotech's megaround, pouring a combined $225 million into gene therapy company Asklepios in exchange for a undisclosed minority stake. The company's founders...
00:47 , Mar 2, 2019 |  BC Extra  |  Company News

Emerging company roundup: Anthos, Maze, Oyster Point

In a week that had at least four companies post venture raises north of $80 million, Maze Therapeutics and Anthos Therapeutics Inc. had the biggest hauls, with financings near or above $200 million. Blackstone partnered...
20:11 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. In exchange for the compound,...
19:38 , Feb 27, 2019 |  BC Extra  |  Company News

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. In exchange for the compound,...
20:07 , Oct 11, 2018 |  BC Extra  |  Company News

Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair

Cancer company VisionGate Inc. (Phoenix, Ariz.) hired John Glasspool as chief operating and strategy officer, a newly created position. He was EVP and head of corporate strategy and customer operations at Baxalta Inc., which Shire...
17:35 , Sep 28, 2018 |  BC Week In Review  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Sept. 26, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400...
20:07 , Sep 26, 2018 |  BC Extra  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Wednesday, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400 million...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
14:42 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Precision BioSciences raises $110M in series B

Genome editing company Precision BioSciences Inc. (Durham, N.C.) raised $110 million in an oversubscribed series B round led by new investor ArrowMark Partners. Other new Investors included Franklin Templeton, Cowen Healthcare Investments, Brace Pharma Capital,...
19:46 , Jun 26, 2018 |  BC Extra  |  Financial News

Precision BioSciences raises $110M in series B

Genome editing company Precision BioSciences Inc. (Durham, N.C.) raised $110 million in an oversubscribed series B round led by new investor ArrowMark Partners. Other new Investors included Franklin Templeton, Cowen Healthcare Investments, Brace Pharma Capital,...